Your browser doesn't support javascript.
loading
Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
Yu, Maria; Brunt, Kate Van; Milicevic, Zvonko; Varnado, Oralee; Boye, Kristina S.
Affiliation
  • Yu M; Eli Lilly and Company, Toronto, Ontario, Canada.
  • Brunt KV; Eli Lilly and Company, Windlesham, United Kingdom.
  • Milicevic Z; Eli Lilly Regional Operations, Vienna, Austria.
  • Varnado O; Eli Lilly and Company, Indianapolis, Indiana.
  • Boye KS; Eli Lilly and Company, Indianapolis, Indiana. Electronic address: boye_kristina_secnik@lilly.com.
Clin Ther ; 39(11): 2284-2295, 2017 Nov.
Article in En | MEDLINE | ID: mdl-29110972
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Immunoglobulin Fc Fragments / Diabetes Mellitus, Type 2 / Glucagon-Like Peptides / Insulin Glargine / Hypoglycemic Agents Type of study: Clinical_trials / Prognostic_studies Aspects: Patient_preference Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Ther Year: 2017 Document type: Article Affiliation country: Canada Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Immunoglobulin Fc Fragments / Diabetes Mellitus, Type 2 / Glucagon-Like Peptides / Insulin Glargine / Hypoglycemic Agents Type of study: Clinical_trials / Prognostic_studies Aspects: Patient_preference Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Ther Year: 2017 Document type: Article Affiliation country: Canada Country of publication: United States